1.29
-0.04(-3.01%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.32 |
| Day High | 1.36 |
| Day Low | 1.26 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.39 |
| Volume | 688,591 |
| Average Volume | 1.82M |
| Market Cap | 94.16M |
| PE | -1.68 |
| EPS | -0.77 |
| Moving Average 50 Days | 1.39 |
| Moving Average 200 Days | 0.98 |
| Change | -0.04 |
If you invested $1000 in Rani Therapeutics Holdings, Inc. (RANI) since IPO date, it would be worth $117.27 as of February 21, 2026 at a share price of $1.29. Whereas If you bought $1000 worth of Rani Therapeutics Holdings, Inc. (RANI) shares 3 years ago, it would be worth $213.22 as of February 21, 2026 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
GlobeNewswire Inc.
Jan 28, 2026 12:00 PM GMT
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the p
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (
Rani Therapeutics to Participate in the Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that